Hospital Medicine

L. Bernardo Menajovsky, MD, MS
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

John Spandorfer, MD
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

Address: L. Bernardo Menajovsky, MD, MS, Thomas Jefferson Thomas Jefferson University Hospital, 833 Chestnut Street East, Suite 701, Philadelphia, PA 19107; e-mail [email protected]

Dr. Menajovsky has indicated that he is on the speakers’ bureau of the Aventis corporation.

Dr. Spandorfer has indicated that he has received grant or research support from the Aventis and Astra Zeneca corporations and is on the speakers’ bureaus of the Aventis and Astra Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

L. Bernardo Menajovsky, MD, MS
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

John Spandorfer, MD
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

Address: L. Bernardo Menajovsky, MD, MS, Thomas Jefferson Thomas Jefferson University Hospital, 833 Chestnut Street East, Suite 701, Philadelphia, PA 19107; e-mail [email protected]

Dr. Menajovsky has indicated that he is on the speakers’ bureau of the Aventis corporation.

Dr. Spandorfer has indicated that he has received grant or research support from the Aventis and Astra Zeneca corporations and is on the speakers’ bureaus of the Aventis and Astra Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

L. Bernardo Menajovsky, MD, MS
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

John Spandorfer, MD
Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

Address: L. Bernardo Menajovsky, MD, MS, Thomas Jefferson Thomas Jefferson University Hospital, 833 Chestnut Street East, Suite 701, Philadelphia, PA 19107; e-mail [email protected]

Dr. Menajovsky has indicated that he is on the speakers’ bureau of the Aventis corporation.

Dr. Spandorfer has indicated that he has received grant or research support from the Aventis and Astra Zeneca corporations and is on the speakers’ bureaus of the Aventis and Astra Zeneca corporations.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Sharon K. Inouye, MD, MPH
Department of Internal Medicine, Yale University School of Medicine

Address: Sharon K Inouye, MD, MPH, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street (DC013K), PO Box 208025, New Haven, CT 06520

This paper was adapted from a presentation given by Dr. Inouye as Visiting Professor Pro Tempore, Department of Medicine, Case Western Reserve University and The Cleveland Clinic Educational Foundation.

Medical Grand Rounds articles are approved by the author but are not peer-reviewed.

Sharon K. Inouye, MD, MPH
Department of Internal Medicine, Yale University School of Medicine

Address: Sharon K Inouye, MD, MPH, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street (DC013K), PO Box 208025, New Haven, CT 06520

This paper was adapted from a presentation given by Dr. Inouye as Visiting Professor Pro Tempore, Department of Medicine, Case Western Reserve University and The Cleveland Clinic Educational Foundation.

Medical Grand Rounds articles are approved by the author but are not peer-reviewed.

Sharon K. Inouye, MD, MPH
Department of Internal Medicine, Yale University School of Medicine

Address: Sharon K Inouye, MD, MPH, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street (DC013K), PO Box 208025, New Haven, CT 06520

This paper was adapted from a presentation given by Dr. Inouye as Visiting Professor Pro Tempore, Department of Medicine, Case Western Reserve University and The Cleveland Clinic Educational Foundation.

Medical Grand Rounds articles are approved by the author but are not peer-reviewed.

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail [email protected]

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Josef Stehlik, MD, MPH
Section of Heart Failure and Transplantation, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

David O. Taylor, MD
Director, Heart Failure Special Care Unit, The Cleveland Clinic Foundation

Address: David Taylor, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Emil P. Lesho, DO
Walter Reed Army Medical Center, Washington, DC

Louise Saullo, CRTT
Greater Hazleton Health Alliance, Hazleton, PA

Szilvia Udvari-Nagy, MD
Cleveland Clinic Florida, Weston, FL

Address: Emil P. Lesho, DO, 611 Forest Glen Road, Silver Spring, MD 20901; e-mail [email protected]

Emil P. Lesho, DO
Walter Reed Army Medical Center, Washington, DC

Louise Saullo, CRTT
Greater Hazleton Health Alliance, Hazleton, PA

Szilvia Udvari-Nagy, MD
Cleveland Clinic Florida, Weston, FL

Address: Emil P. Lesho, DO, 611 Forest Glen Road, Silver Spring, MD 20901; e-mail [email protected]

Emil P. Lesho, DO
Walter Reed Army Medical Center, Washington, DC

Louise Saullo, CRTT
Greater Hazleton Health Alliance, Hazleton, PA

Szilvia Udvari-Nagy, MD
Cleveland Clinic Florida, Weston, FL

Address: Emil P. Lesho, DO, 611 Forest Glen Road, Silver Spring, MD 20901; e-mail [email protected]

Benjamin J. Freda, DO
Department of Nephrology and Hypertension, The Cleveland Clinic Foundation

Michael B. Davidson, DO
Department of Internal Medicine, The Cleveland Clinic Foundation

Phillip M. Hall, MD
Staff Consultant, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation

Address: Phillip M. Hall, MD, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation, A51, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Benjamin J. Freda, DO
Department of Nephrology and Hypertension, The Cleveland Clinic Foundation

Michael B. Davidson, DO
Department of Internal Medicine, The Cleveland Clinic Foundation

Phillip M. Hall, MD
Staff Consultant, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation

Address: Phillip M. Hall, MD, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation, A51, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Benjamin J. Freda, DO
Department of Nephrology and Hypertension, The Cleveland Clinic Foundation

Michael B. Davidson, DO
Department of Internal Medicine, The Cleveland Clinic Foundation

Phillip M. Hall, MD
Staff Consultant, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation

Address: Phillip M. Hall, MD, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation, A51, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Mansour A. Parsi, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Ashish Atreja, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Nizar N. Zein, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Mansour A. Parsi, MD, Department of Gastroenterology and Hepatology, A31, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Mansour A. Parsi, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Ashish Atreja, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Nizar N. Zein, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Mansour A. Parsi, MD, Department of Gastroenterology and Hepatology, A31, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Mansour A. Parsi, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Ashish Atreja, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Nizar N. Zein, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Mansour A. Parsi, MD, Department of Gastroenterology and Hepatology, A31, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Richard M. Salvino, MD
Department of Gastroenterology, MetroHealth Medical Center, Cleveland, OH

Robert S. Dechicco, MS, RD, LD, CNSD
Manager, Nutrition Support Dietetics, Department of Nutrition Support and Vascular Access, The Cleveland Clinic Foundation

Douglas L. Seidner, MD, CNSP
Director, Department of Nutrition Support and Vascular Access; Program Director, Fellowship in Clinical Nutrition, Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Douglas L. Seidner, MD, Department of Gastroenterology and Hepatology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Richard M. Salvino, MD
Department of Gastroenterology, MetroHealth Medical Center, Cleveland, OH

Robert S. Dechicco, MS, RD, LD, CNSD
Manager, Nutrition Support Dietetics, Department of Nutrition Support and Vascular Access, The Cleveland Clinic Foundation

Douglas L. Seidner, MD, CNSP
Director, Department of Nutrition Support and Vascular Access; Program Director, Fellowship in Clinical Nutrition, Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Douglas L. Seidner, MD, Department of Gastroenterology and Hepatology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Richard M. Salvino, MD
Department of Gastroenterology, MetroHealth Medical Center, Cleveland, OH

Robert S. Dechicco, MS, RD, LD, CNSD
Manager, Nutrition Support Dietetics, Department of Nutrition Support and Vascular Access, The Cleveland Clinic Foundation

Douglas L. Seidner, MD, CNSP
Director, Department of Nutrition Support and Vascular Access; Program Director, Fellowship in Clinical Nutrition, Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Douglas L. Seidner, MD, Department of Gastroenterology and Hepatology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195